Filtros de búsqueda

Lista de obras de Nancy L Bartlett

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation

artículo científico publicado en 2011

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.

artículo científico publicado en 2004

944OBRENTUXIMAB VEDOTIN IN COMBINATION WITH CHP IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED CD30+ PERIPHERAL T-CELL LYMPHOMAS (PTCL): 2-YEAR FOLLOW-UP

artículo científico publicado en 2014

A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma

artículo científico publicado en 2015

A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma

artículo científico publicado en 2017

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

artículo científico publicado en 2009

A Young Woman With Blurred Vision and Distal Paresthesias.

artículo científico publicado en 2015

A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphoma

scientific article published on 08 October 2020

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

artículo científico publicado en 2007

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

scientific article published on 28 January 2019

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

scientific article published on 30 July 2020

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

artículo científico publicado en 2011

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies

artículo científico publicado en 2011

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

artículo científico publicado en 2014

A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.

artículo científico publicado en 2011

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

artículo científico publicado en 2017

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

artículo científico publicado en 2015

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.

artículo científico publicado en 2011

A pilot study of lenalidomide maintenance therapy after autologous transplantation in relapsed or refractory classical Hodgkin lymphoma

scientific article published on 20 August 2020

A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma

artículo científico publicado en 2016

ABVD plus rituximab ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

artículo científico publicado en 2018

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma

artículo científico publicado en 2014

Anaplastic large-cell lymphoma with aberrant expression of multiple cytokeratins masquerading as metastatic carcinoma of unknown primary

artículo científico publicado en 2013

Anti-CD30 Antibodies for Hodgkin lymphoma.

artículo científico publicado en 2010

Antibodies for the treatment of diffuse large cell lymphoma.

artículo científico publicado en 2003

Assessment of cellular proliferation in tumors by PET using 18F-ISO-1.

artículo científico publicado en 2013

Assessment of knowledge about cancer pain management by physicians in training ⬇️

artículo científico publicado el 1 de julio de 1997

Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492

artículo científico publicado en 2000

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

artículo científico publicado en 2017

Barriers to clinical trial participation by older women with breast cancer.

artículo científico publicado en 2003

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study

artículo científico publicado en 2010

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

artículo científico publicado en 2001

Biologic agents in the management of Hodgkin lymphoma.

artículo científico

Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy

scientific article published on 30 October 2020

Blinatumomab for the treatment of B-cell lymphoma.

artículo científico publicado en 2015

Bone marrow staging in patients with non-Hodgkin's lymphoma: is flow cytometry a useful test?

scientific article published on 01 March 1998

Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403 ⬇️

artículo científico publicado en 2020

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

scientific article published on 07 January 2019

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

artículo científico publicado en 2017

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

artículo científico publicado en 2010

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

artículo científico publicado en 2012

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

artículo científico publicado en 2016

Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.

artículo científico

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

artículo científico publicado en 2015

Brentuximab vedotin for the treatment of CD30+ lymphomas.

artículo científico publicado en 2011

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

scientific article published on 24 February 2014

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study

artículo científico publicado en 2014

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies

artículo científico publicado en 2012

Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial

artículo científico publicado en 2020

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

artículo científico publicado en 2018

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

scientific article published on 01 March 2020

Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report

artículo científico publicado en 1995

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

artículo científico publicado en 2018

CAR-T therapy in Solid Organ Transplant Recipients with Treatment Refractory Post Transplant Lymphoproliferative Disorder

artículo científico publicado en 2020

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

artículo científico publicado en 2020

CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma.

artículo científico publicado en 2014

CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas

artículo científico publicado en 2018

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma

scientific article published on 01 November 2018

Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience

Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)

article

Chemotherapy-Induced First Bite Syndrome: A Case Report in a Patient With Hodgkin Lymphoma

artículo científico publicado en 2019

Chimeric Antigen Receptor T-Cell Therapy

artículo científico publicado en 2018

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015

artículo científico publicado en 2015

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration

artículo científico publicado en 2016

Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma.

artículo científico publicado en 2015

Composite diffuse large B-cell lymphoma and precursor B lymphoblastic lymphoma presenting as a double-hit lymphoma with MYC and BCL2 translocation

scientific article published on 21 July 2011

Cyclin D1 as an aid in the diagnosis of mantle cell lymphoma in skin biopsies: a case report.

artículo científico publicado en 2001

Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind,

artículo científico publicado en 2015

Diffuse Large B-Cell Lymphoma Version 1.2016

scientific article published on 01 February 2016

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

artículo científico publicado en 2019

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

artículo científico publicado en 2018

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

artículo científico publicado en 2011

Drug development for recurrent and refractory classical Hodgkin lymphoma

artículo científico publicado en 2009

Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.

artículo científico publicado en 2017

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era

artículo científico publicado en 2015

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study

artículo científico publicado en 2014

Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome

artículo científico publicado en 2015

Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma

artículo científico publicado en 2011

Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies

artículo científico publicado en 2014

Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome

scientific article published on 29 May 2019

Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

artículo científico publicado en 2020

Fine-Tuning the Treatment of Hodgkin's Lymphoma.

artículo científico publicado en 2016

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

artículo científico publicado en 2020

Five-Year Outcomes for Frontline Brentuximab Vedotin with CHP for CD30 Expressing Peripheral T-Cell Lymphomas.

artículo científico publicado en 2018

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma

scientific article published on 01 October 2019

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

artículo científico publicado en 2017

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity

artículo científico publicado en 2005

Follicular large-cell lymphoma: intermediate or low grade?

artículo científico publicado en 1994

Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.

artículo científico publicado en 2004

Formulating a Treatment Plan in Suspected Lymphoma: Ultrasound-Guided Core Needle Biopsy Versus Core Needle Biopsy and Fine-Needle Aspiration of Peripheral Lymph Nodes

scientific article published on 25 July 2018

Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

artículo científico publicado en 2018

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

artículo científico publicado en 2007

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma

artículo científico publicado en 2012

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

artículo científico publicado en 2018

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

artículo científico publicado en 2015

High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 cor

artículo científico publicado en 2008

High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis

artículo científico publicado en 2013

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

artículo científico publicado en 2016

Hodgkin's disease: prognostic factors and short-course regimens.

artículo científico publicado en 2000

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

artículo científico publicado en 2002

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia ⬇️

artículo científico publicado en 2015

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

artículo científico publicado en 2015

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

artículo científico publicado en 2012

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

artículo científico publicado en 2009

Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort.

artículo científico publicado en 2018

Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience

artículo científico publicado en 2019

In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma

artículo científico publicado en 2018

Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma

artículo científico publicado en 2012

Inflammatory carcinoma of the breast: treatment results on 107 patients

artículo científico publicado en 1989

Interdigitating dendritic reticulum cell tumor of lymph nodes: case report with differential diagnostic considerations

artículo científico publicado en 2003

Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

artículo científico publicado en 2012

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

artículo científico publicado en 2017

Intravascular lymphoma associated with endocrine dysfunction: a report of four cases and a review of the literature.

artículo científico publicado en 1999

Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.

artículo científico publicado en 2017

Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission.

artículo científico publicado en 2014

Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.

artículo científico publicado en 2017

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

artículo científico publicado en 2018

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial

artículo científico publicado en 2020

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.

artículo científico publicado en 2013

MACOP-B ± radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford Results According to Prognostic Indices ⬇️

artículo científico publicado el 15 de junio de 1993

Magnetic resonance image guided radiation therapy for primary splenic diffuse large B-cell lymphoma: A teaching case

artículo científico publicado en 2016

Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma.

artículo científico publicado en 2015

Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.

artículo científico publicado en 2018

Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma

artículo científico publicado en 2014

Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study

artículo científico publicado en 2017

Modern treatment of Hodgkin lymphoma.

artículo científico publicado en 2008

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

artículo científico publicado en 2020

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

scientific article published on 01 June 2019

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.

artículo científico publicado en 2017

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

artículo científico publicado en 2016

Non-Hodgkin's Lymphomas, version 3.2012

artículo científico publicado en 2012

Non-Hodgkin's lymphomas

artículo científico publicado en 2011

Non-Hodgkin's lymphomas, version 1.2013.

artículo científico publicado en 2013

Non-Hodgkin's lymphomas, version 2.2014

artículo científico publicado en 2014

Non-Hodgkin's lymphomas, version 4.2014.

artículo científico publicado en 2014

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

artículo científico publicado en 2014

Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.

artículo científico publicado en 2017

Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.

artículo científico publicado en 2017

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

artículo científico publicado en 2020

Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)

artículo científico publicado en 2015

Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.

artículo científico publicado en 2015

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

Parameters for Validating a Hospital Pneumatic Tube System

scientific article published on 26 February 2019

Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma.

artículo científico publicado en 2016

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

artículo científico publicado en 2017

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.

artículo científico publicado en 2016

Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)

scientific article published on 05 February 2019

Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.

artículo científico publicado en 2002

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

artículo científico publicado en 1994

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

artículo científico publicado en 2015

Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.

artículo científico publicado en 2008

Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma

artículo científico publicado en 2012

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

artículo científico publicado en 2013

Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma

artículo científico publicado en 2020

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study

artículo científico publicado en 2019

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001

artículo científico publicado en 2020

Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816

artículo científico publicado en 2020

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

artículo científico publicado en 2011

Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study

artículo científico publicado en 2012

Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial

scientific article published on 13 March 2020

Prognostic factors in inflammatory breast cancer. Univariate and multivariate analysis.

artículo científico publicado en 1989

Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation

artículo científico publicado en 2011

Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin

artículo científico publicado en 2012

Progressive multifocal leukoencephalopathy treated with nivolumab

artículo científico publicado en 2019

Protein losing enteropathy associated with follicular lymphoma of the small bowel.

artículo científico publicado en 2009

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia

artículo científico publicado en 2003

Radiation for early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a double-edged sword?

artículo científico publicado en 2016

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial

artículo científico publicado en 2015

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).

artículo científico publicado en 2015

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

artículo científico publicado en 2002

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)

artículo científico publicado en 2012

Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance)

scientific article published on 07 June 2019

Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.

artículo científico publicado en 2016

Reply to T.M. Weis et al

artículo científico publicado en 2019

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

artículo científico publicado en 2012

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

artículo científico publicado en 2014

Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial

scientific article published on 13 February 2003

Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers.

artículo científico publicado en 2014

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

artículo científico publicado en 2018

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial

artículo científico publicado en 2005

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

scientific article published on 01 March 2020

Role of routine imaging in lymphoma

artículo científico publicado en 2011

SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma.

artículo científico publicado en 2018

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.

artículo científico publicado en 2017

Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906

scientific article published on 01 August 2006

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism

artículo científico publicado en 2010

Serum Markers in Germ Cell Neoplasms ⬇️

artículo científico publicado el 1 de diciembre de 1991

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study

artículo científico publicado en 2019

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

artículo científico publicado en 2007

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.

artículo científico publicado en 2017

Solid, low-attenuation splenic lesions on computed tomography in patients with indolent lymphoma often signal transformation: a series of ten patients.

artículo científico publicado en 2012

Splenic pathology in myelodysplasia: a report of 13 cases with clinical correlation

artículo científico publicado en 1998

Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial

artículo científico publicado en 2002

Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials

scientific article published on 01 September 2002

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2

artículo científico publicado en 2018

Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

scientific article published on 01 May 2019

Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.

artículo científico publicado en 2008

The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas

artículo científico publicado en 2015

The Present: Optimizing Therapy—Too Much or Too Little? ⬇️

artículo científico publicado el 1 de enero de 2010

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).

artículo científico publicado en 2013

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496

artículo científico publicado en 2013

The justification of vincristine dose capping: tradition, tradition…tradition!

artículo científico publicado en 2020

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

scientific article published on 21 December 2018

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience

artículo científico publicado en 2014

Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy.

artículo científico publicado en 2005

Therapy in primary mediastinal B-cell lymphoma

artículo científico publicado en 2013

Therapy of relapsed Hodgkin lymphoma.

artículo científico publicado en 2007

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)

artículo científico publicado en 2014

To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma

artículo científico publicado en 2019

Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle

artículo científico publicado en 2020

Treatment of aggressive histology lymphoma ⬇️

artículo científico publicado el 1 de septiembre de 1997

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

artículo científico publicado en 2012

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

scientific article published on 11 April 2016

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Scientific article published on 2 Dec 2016

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

artículo científico publicado en 2018

Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?

artículo científico

Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.

artículo científico publicado en 2004

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda